176 related articles for article (PubMed ID: 38066633)
1. A novel BRAF::PTPRN2 fusion in meningioma: a case report.
Sadagopan NS; Nandoliya KR; Youngblood MW; Horbinski CM; Ahrendsen JT; Magill ST
Acta Neuropathol Commun; 2023 Dec; 11(1):194. PubMed ID: 38066633
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
Jones DT; Kocialkowski S; Liu L; Pearson DM; Ichimura K; Collins VP
Oncogene; 2009 May; 28(20):2119-23. PubMed ID: 19363522
[TBL] [Abstract][Full Text] [Related]
4. Detection and genomic analysis of BRAF fusions in Juvenile Pilocytic Astrocytoma through the combination and integration of multi-omic data.
Zwaig M; Baguette A; Hu B; Johnston M; Lakkis H; Nakada EM; Faury D; Juretic N; Ellezam B; Weil AG; Karamchandani J; Majewski J; Blanchette M; Taylor MD; Gallo M; Kleinman CL; Jabado N; Ragoussis J
BMC Cancer; 2022 Dec; 22(1):1297. PubMed ID: 36503484
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
[TBL] [Abstract][Full Text] [Related]
6. Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature.
Mordechai O; Postovsky S; Vlodavsky E; Eran A; Constantini S; Dotan E; Cagnano E; Weyl-Ben-Arush M
Pediatr Hematol Oncol; 2015 Apr; 32(3):207-11. PubMed ID: 25116269
[TBL] [Abstract][Full Text] [Related]
7. Chromothripsis in an Early Recurrent Chordoid Meningioma.
Baltus C; Toffoli S; London F; Delrée P; Gilliard C; Gustin T
World Neurosurg; 2019 Oct; 130():380-385. PubMed ID: 31295612
[TBL] [Abstract][Full Text] [Related]
8. Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas.
Roth JJ; Santi M; Pollock AN; Harding BN; Rorke-Adams LB; Tooke LS; Biegel JA
Brain Pathol; 2015 Mar; 25(2):182-92. PubMed ID: 25040262
[TBL] [Abstract][Full Text] [Related]
9. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
10. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.
Forshew T; Tatevossian RG; Lawson AR; Ma J; Neale G; Ogunkolade BW; Jones TA; Aarum J; Dalton J; Bailey S; Chaplin T; Carter RL; Gajjar A; Broniscer A; Young BD; Ellison DW; Sheer D
J Pathol; 2009 Jun; 218(2):172-81. PubMed ID: 19373855
[TBL] [Abstract][Full Text] [Related]
11. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
12. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.
Lin A; Rodriguez FJ; Karajannis MA; Williams SC; Legault G; Zagzag D; Burger PC; Allen JC; Eberhart CG; Bar EE
J Neuropathol Exp Neurol; 2012 Jan; 71(1):66-72. PubMed ID: 22157620
[TBL] [Abstract][Full Text] [Related]
13. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
Tomić TT; Olausson J; Wilzén A; Sabel M; Truvé K; Sjögren H; Dósa S; Tisell M; Lannering B; Enlund F; Martinsson T; Åman P; Abel F
PLoS One; 2017; 12(4):e0175638. PubMed ID: 28448514
[TBL] [Abstract][Full Text] [Related]
14. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
[TBL] [Abstract][Full Text] [Related]
15. Whole Chromosome 7 Gain Predicts Higher Risk of Recurrence in Pediatric Pilocytic Astrocytomas Independently From KIAA1549-BRAF Fusion Status.
Roth JJ; Fierst TM; Waanders AJ; Yimei L; Biegel JA; Santi M
J Neuropathol Exp Neurol; 2016 Apr; 75(4):306-15. PubMed ID: 26945035
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
Ciampi R; Knauf JA; Kerler R; Gandhi M; Zhu Z; Nikiforova MN; Rabes HM; Fagin JA; Nikiforov YE
J Clin Invest; 2005 Jan; 115(1):94-101. PubMed ID: 15630448
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas.
Kumar A; Pathak P; Purkait S; Faruq M; Jha P; Mallick S; Suri V; Sharma MC; Suri A; Sarkar C
Cancer Genet; 2015 Mar; 208(3):91-5. PubMed ID: 25794445
[TBL] [Abstract][Full Text] [Related]
18. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential.
Jeuken JW; Wesseling P
J Pathol; 2010 Dec; 222(4):324-8. PubMed ID: 20976706
[TBL] [Abstract][Full Text] [Related]
19. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
20. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.
Botton T; Talevich E; Mishra VK; Zhang T; Shain AH; Berquet C; Gagnon A; Judson RL; Ballotti R; Ribas A; Herlyn M; Rocchi S; Brown KM; Hayward NK; Yeh I; Bastian BC
Cell Rep; 2019 Oct; 29(3):573-588.e7. PubMed ID: 31618628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
